134 related articles for article (PubMed ID: 1313110)
1. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
2. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
3. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
4. 2-[[(4-Amino-2-pyridyl)methyl]sulfinyl]benzimidazole H+/K+-ATPase inhibitors. The relationship between pyridine basicity, stability, and activity.
Ife RJ; Dyke CA; Keeling DJ; Meenan E; Meeson ML; Parsons ME; Price CA; Theobald CJ; Underwood AH
J Med Chem; 1989 Aug; 32(8):1970-7. PubMed ID: 2547073
[TBL] [Abstract][Full Text] [Related]
5. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
6. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.
Besancon M; Simon A; Sachs G; Shin JM
J Biol Chem; 1997 Sep; 272(36):22438-46. PubMed ID: 9278394
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
8. [Discovery and development of the proton pump inhibitor].
Igata H; Okabe S
Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
[TBL] [Abstract][Full Text] [Related]
9. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor.
Morii M; Takata H; Fujisaki H; Takeguchi N
Biochem Pharmacol; 1990 Feb; 39(4):661-7. PubMed ID: 2154989
[TBL] [Abstract][Full Text] [Related]
10. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Postius S; Bräuer U; Kromer W
Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
[TBL] [Abstract][Full Text] [Related]
11. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates.
Kromer W; Krüger U; Huber R; Hartmann M; Steinijans VW
Pharmacology; 1998 Feb; 56(2):57-70. PubMed ID: 9494064
[TBL] [Abstract][Full Text] [Related]
12. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
13. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
Hanauer G; Graf U; Meissner T
Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole, a specific inhibitor of gastric (H+-K+)-ATPase, is a H+-activated oxidizing agent of sulfhydryl groups.
Im WB; Sih JC; Blakeman DP; McGrath JP
J Biol Chem; 1985 Apr; 260(8):4591-7. PubMed ID: 2985559
[TBL] [Abstract][Full Text] [Related]
15. Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors.
Sih JC; Im WB; Robert A; Graber DR; Blakeman DP
J Med Chem; 1991 Mar; 34(3):1049-62. PubMed ID: 1848293
[TBL] [Abstract][Full Text] [Related]
16. The sulphoxide moiety of substituted benzimidazoles is essential for inhibition of parietal cell K+/H+-ATPase.
Beil W; Eltze M; Heintze K; Klemm K; Riedel R; Schudt C; Sewing KF; Simon A
Br J Pharmacol; 1986 Jun; 88(2):389-95. PubMed ID: 3015311
[TBL] [Abstract][Full Text] [Related]
17. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
[TBL] [Abstract][Full Text] [Related]
18. Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.
Beil W; Staar U; Sewing KF
Eur J Pharmacol; 1992 Aug; 218(2-3):265-71. PubMed ID: 1330598
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
20. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.
Fellenius E; Berglindh T; Sachs G; Olbe L; Elander B; Sjöstrand SE; Wallmark B
Nature; 1981 Mar; 290(5802):159-61. PubMed ID: 6259537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]